Navigation Links
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association

* Ozarelix Effective in Improving Symptoms and Urine Flow, With Long Lasting Effect in Phase 2 Study

IRVINE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., today announced Phase 2 safety and efficacy data for ozarelix, the Company's drug candidate for the treatment of benign prostatic hypertrophy (BPH), at the American Urology Association Annual Meeting held at the Anaheim Convention Center in Anaheim, California on Tuesday, May 22, 2007.

"The results of this study indicate a significant and sustained degree of benefit, higher than what is usually seen with current treatments of BPH," said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals. "We have recently completed enrollment in a Phase 2b study in the U.S. Once we have preliminary results from this Phase 2b trial, we plan to begin a Phase 3 trial, which we expect to begin later this year. Results from the Phase 2b trial will aid in the design of the Phase 3 trial. We believe that ozarelix could help serve the large unmet medical need for more effective BPH treatments."

The efficacy and safety of ozarelix, a GnRH antagonist, given intramuscularly (IM) was assessed in men with moderate to severe Lower Urinary Tract Symptoms (LUTS) due to BPH in a randomized, double-blind, placebo- controlled, multi-center, Phase 2 dose-ranging study.

Patients (N=144) meeting the inclusion criteria were randomly allocated to one of five treatment groups:

    Group 1:  placebo,

    Group 2:  5mg ozarelix on Day 1 + 5mg ozarelix on Day 15;

    Group 3:  10mg ozarelix on Day 1 +10mg ozarelix on Day 15;

    Group 4:  15mg ozarelix on Day 1 + 15mg ozarelix on Day 15; and,

    Group 5:  20mg ozarelix on Day 1 only.

Study participants were followed for six months. The primary efficacy endpoint was a change in the International Prostate Symposium Score (IPS
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/22/2013)... STEPh, Inc., a full service medical communications ... web site ( http://www.stephreports.com ) dedicated to ... STEPh Reports STEPh Reports are comprehensive critical ... STEPh Report assesses the competitive landscape by individual drug ... and specific key issues.  STEPh Reports are written by ...
(Date:5/22/2013)... , May 22, 2013 MEDIFIRST SOLUTIONS, INC. ... update shareholders about some recent company developments. As Medifirst ... avenues of communication with shareholders. Integrating social media into ... Facebook page and will post updates on Twitter.  The ... is #medifirstusa. Says CEO ...
(Date:5/22/2013)... , May 22, 2013 Ranbaxy ... Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on ... in recent years to address past conduct under ... Daiichi Sankyo continues to support ... the conduct of the past which led to ...
Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Medifirst Solutions, Inc. Announces Update To Shareholders 2
... 9, 2011 ProTron Technologies announces a new approach ... the patented Stethotron® Cerebral Stethoscope. In the ... In 50% of ruptured aneurysms, patients in the age ... of the major factors leading to aneurysm is vascular ...
... Westside Medical Imaging of Beverly Hills announces the ... a 3 Tesla magnet to monitor the effects of cholesterol ... Hooman Madyoon and Michael Duffy of ... adopted 3 Tesla magnetic resonance imaging (MRI) using specialized vascular ...
Cached Medicine Technology:Westside Medical Imaging Uses High Resolution Magnetic Imaging to Monitor Effects of Cholesterol Drugs on Atherosclerosis 2
(Date:5/22/2013)... Go Classy the Original Nudist Travel ... of their newest website http://www.Desire-Mexico.com . The seductively ... Desire Resorts have become the premier Nudist and Lifestyle ... total liberation while allowing you to enjoy a deluxe ... Classy Tours / Caribbean-Hideaways. He goes on to say ...
(Date:5/22/2013)... May 22 (HealthDay News) -- Fish oil supplements ... diabetes, new research suggests. The supplements, ... of a hormone called adiponectin that,s linked to ... this hormone in the bloodstream have also been ... "While prior animal studies found fish oil ...
(Date:5/22/2013)... 1,000 mg per day can help women live longer, ... Langsetmo, a Ph.D. Research Associate at McGill University, and ... Endocrinology and Metabolism in the Department of Medicine of ... Disorders axis at the Research Institute of the McGill ... Journal of Clinical Endocrinology & Metabolism (JCEM). ...
(Date:5/22/2013)... The newest member of TeethWhiteningforFree.com is Dr. ... Alabama graduate, Dr. Sanderson provides professional dental care to ... he extends complimentary teeth whitening to his patients who ... up. Only a dental professional can decide if the ... , Teeth whitening is an easy way ...
(Date:5/22/2013)... DiscountFurnaceFilter.com now offers a vast ... furnace filters, dehumidifiers, fans, aroma diffusers, dehumidifiers and ... Stadler Form's product line to their selection! Stadler ... aroma diffusers and dehumidifiers) to accentuate anyone’s home ... the perfect combination of design and functionality. Otto ...
Breaking Medicine News(10 mins):Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2Health News:Fish Oil Pills Might Cut Diabetes Risk, Researchers Say 2Health News:Calcium supplements linked to longer lifespans in women 2Health News:Dr. James Sanderson, Jr. Of SanDentistry in Hoover, Alabama Joins the TeethWhiteningforFree.com Family 2Health News:DiscountFurnaceFilter.com Now Offers Stadler Form Products - Providing Solutions to All Your Summer Needs 2
... 29 The National Patient,Safety Foundation,s theme this ... the importance of improving healthcare as a joint,effort ... Supporting National Patient Safety Awareness Week, March 2-8, ... ) urges communities to,actively partner with local hospitals ...
... Cardiogenesis,Corporation (Pink Sheets: CGCP), a leading developer ... today announced that,it will delay its earnings release ... full year ended December 31, 2007. The earnings ... Tuesday, March 4,2008., The Company noted that ...
... the Only Provider to Offer Practice Management and ... of Mental Health Care Providers, GREAT RIVER, ... provider of enterprise-wide software and services for health ... Therapist,Helper product suite and operations from Nightingale VantageMed,Corporation, ...
... PRINCETON, N.J., Feb. 29 Orchid Cellmark Inc.,(Nasdaq: ... testing,services, will release its fourth quarter and full year ... 7:00 am EST, and is,hosting a conference call and ... the same day. Management will discuss financial results for ...
... heart, liver and lung transplants at UCSF Medical ... according to new data compiled by the Scientific ... Released on January 11, the report measures performance ... facilities in the United States, including waiting list ...
... and benefits still outweigh risks, experts say , , FRIDAY, ... the risk for tendon problems, French researchers report. , ... rare, considering the huge number of statin prescriptions," wrote ... March issue of Arthritis Care and Research , ...
Cached Medicine News:Health News:Encision Supports National Patient Safety Awareness Week 2Health News:Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call 2Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 2Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 3Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 4Health News:Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2Health News:Survival rates exceed national averages for UCSF heart, liver and lung transplant programs 2Health News:Cholesterol-Lowering Statins Tied to Tendon Woes 2Health News:Cholesterol-Lowering Statins Tied to Tendon Woes 3
... the highest g-force ever. But optimal productivity ... Optima MAX combines maximum force, capacity, and ... that's worlds apart from any other system. ... enhanced efficiency, Optima takes productivity to the ...
... generating 694,000 x g at ... Beckman Coulter's Optima L-90K Ultracentrifuge ... separations in less time. This ... a broad range of superb ...
... With the ability to provide a simple, ... in lipemic samples), the Airfuge CLS delivers ... can be cleaned in 10 minutes, eliminating ... tabletop centrifuge: Reaches top speed in as ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
Medicine Products: